Bioavailability and bioequivalence: Focus on physiological factors and variability

Pharmaceutical Research

Volumn 25, Issue 8, 2008, Pages 1956-1962

  Karalis, Vangelis ^a   Macheras, Panos ^a   Van Peer, Achiel ^b   Shah, Vinod P ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b JOHNSON AND JOHNSON   (United States)

^c International Pharmaceutical Federation   (United States)

Author keywords

Bioavailability and bioequivalence; Highly variable drugs; Impact of variability on BE studies; Physiological factors affecting drug absorption

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; DRUG METABOLITE; PARACETAMOL; RANITIDINE;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSFORMATION; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GASTROINTESTINAL TRACT; INTESTINE TRANSIT TIME; MODEL; PRIORITY JOURNAL; STOMACH EMPTYING; SUSPENSION; TABLET;

ANIMALS; BIOLOGICAL AVAILABILITY; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; THERAPEUTIC EQUIVALENCY;

EID: 46749104406     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9645-9     Document Type: Conference Paper

References (49)

1. D. Melnick, M. Hochberg, and B. L. Oser. Physiological availability of the vitamins. I. The human bioassasy technique. J. Nutr. 30:67-79 (1945).
2. A. Morrison, D. Chapman, and J. Campbell. Further studies on the relation between in vitro disintegration time of tablets and the urinary excretion rates of riboflavin. J. Am. Pharm. Assoc. 48:634-637 (1959).
3. A. Morrison, and J. Campbell. The relationship between physiological availability of salicylates and riboflavin and in vitro disintegration time of enteric coated tablets. J. Am. Pharm. Assoc. 49:473-478 (1960).
4. E. Middleton, J. Davies, and A. Morrison. Relationship between rate of dissolution, disintegration time, and physiological availability of riboflavin in sugar-coated tablets. J. Pharm. Sci. 53:1378-1380 (1964).
5. G. Levy. Comparison of dissolution and absorption rates of different commercial aspirin tablets. J. Pharm. Sci. 50:388-392 (1961).
6. G. Levy. Effect of particle size on dissolution and gastrointestinal absorption rates of pharmaceuticals. Am. J. Pharm. Sci. 135:78-92 (1963).
7. A. Glazko, A. Kinkel, W. Alegnani, and E. Holmes. An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects. Clin. Pharmacol. Ther. 9(4):472-483 (1968).
8. D. Fleisher, C. Li, Y. Zhou, L.H. Pao, and A. Karim. Drug, meal and formulation interactions influencing drug absorption after oral administration clinical implications. Clin. Pharmacokinet. 36(3):233-254 (1999).
9. P. G. Welling. J. Pharmacokinet. Biopharm. 5:291-334 (1977).
10. L. Olanoff, T. Walle, T. Cowart, W. Walle, M. Oexmann, and E. Conradi. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin. Pharmacol. Ther. 40:408-414 (1986).
11. S. Gupta, and L. Benet. High-fat meals increase the clearance of cyclosporine. Pharm. Res. 7:46-48 (1990).
12. J. Griffin. Drug interactions occurring during absorption from the gastrointestinal tract. Pharmacol. Ther. 15:79-88 (1981).
13. I. Walter-Sack. The influence of nutrition on the systemic availability of drugs. Part I: drug absorption. Klin. Wochenschr. 65:927-935 (1987).
14. G. Amidon, H. Lennernas, V. Shah, and J. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).
15. M. Mayersohn. Principles of drug absorption. In G. S. Banker, and C. T. Rhodes (eds.), Modern Pharmaceutics, 2nd ed, Marcel Dekker, New York, 1990, pp. 23-90.
16. M. Gibaldi. Biopharmaceutics and clinical Pharmacokinetics, 4th ed. Lea and Lea Febiger, Philadelphia, 1991.
17. P. Shore, B. Brodie, and C. Hogben. The gastric secretion of drugs: a pH partition hypothesis. J. Pharmacol. Exp. Ther. 119(3):361-369 (1957).
18. N. Ho, J. Park, P. Ni, and W. Higuchi. Advanced quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. In W. Crouthanel, and A. C. Sarapu (eds.), Animal models for oral drug delivery in man: In situ and in vivo approaches, American Pharmaceutical Association, Washington, DC, 1983, pp. 27-106.
19. J. Dressman, G. Amidon, and D. Fleisher. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 74(5):588-589 (1985).
20. Simcyp® Population-based ADME simulator.
21. M. Chen, and A. Jackson. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect. Pharm. Res. 8(1):25-32 (1991).
22. M. Chen, and A. Jackson. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect. Pharm. Res. 12(5):700-708 (1995).
23. A. Jackson. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect. Pharm. Res. 17(11):1432-1436 (2000).
24. A. Jackson, G. Robbie, and P. Marroum. Metabolites and bioequivalence: past and present. Clin Pharmacokinet. 43(10):655-672 (2004).
25. K. Midha, M. Rawson, and J. Hubbard. The role of metabolites in bioequivalence. Pharm. Res. 21(8):1331-1344 (2004).
26. D. Tam, R. Tirona, and K. Pang. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab. Dispos. 31(4):373-383 (2003).
27. B. Agoram, W. Woltosz, and M. Bolger. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50:S41-S67 (2001).
28. C. Wu, and L. Benet. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22(1):11-23 (2005).
29. I. McGilveray, K. Midha, J. Skelly, S. Dighe, J. Doluisio, I. French, A. Karim, and R. Burford. Consensus report from "Bio International '89": issues in the evaluation of bioavailability data. J Pharm. Sci. 79(10):945-946 (1990).
30. H. Blume, and K. Midha. Bio-International '92, Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies. J. Pharm. Sci. 82(11):1186-1189 (1993).
31. T. Tozer, F. Bois, W. Hauck, M. Chen, and R. Williams. Absorption rate vs. exposure: which is more useful for bioequivalence testing. Pharm. Res. 13(3):453-456 (1996).
32. Committee for Proprietary Medicinal Products (CPMP). European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence, London, 2001.
33. Center for Drug Evaluation and Research (CDER), Food and Drug Administration, Statistical Approaches to Establishing Bioequivalence. Rockville, MD, 2001.
34. Center for Drug Evaluation and Research (CDER), Food and Drug Administration. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products. General Considerations, Rockville, MD, 2003.
35. H. Blume, M. Elze, H. Potthast, and B. Schug. Practical strategies and design advantages in highly variable drug studies: multiple dose and replicate administration design. In H. H. Blume and K. Midha (eds.), Bio-international '92: Bioavailability, Bioequivalence, and Pharmacokinetic Studies. Medpharm, Stuttgart, 1995, pp. 117-122.
36. K. Midha, M. Rawson J. Hubbard, E. Ormsby. Practical strategies and design advantages in highly variable drug studies: replicate design. In H. H. Blume and K. Midha (eds.), Bio-international'92: Bioavailability, Bioequivalence, and Pharmacokinetic Studies. Medpharm, Stuttgart, 1995, pp. 117-122.
37. V. Shah, A. Yacobi, W. Barr, L. Benet, D. Breimer, M. Dobrinska, L. Endrenyi, W. Fairweather, W. Gillespie, M. Gonzales, J. Hooper, A. Jackson, L. Lesko, K. Midha, P. Noonan, R. Patnaik, and R. Williams. Evaluation of orally administered highly variable drugs and drug formulations. Pharm. Res. 13:1590-1594 (1996).
38. A. Jackson. Prediction of steady-state bioequivalence relationships using single dose data I-linear kinetics. Biopharm. Drug Dispos. 8(5):483-496 (1987).
39. Federal Register. 42:1621-1653 (1977).
40. Federal Register. 45:56832 (1980).
41. S. Dighe. Bioequivalence: emerging policies and procedures', presented at Drug Information Association, Hilton Head, SC (1985).
42. A. Boddy, F. Snikeris, R. Kringle, G. Wei, J. Oppermann, and K. Midha. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs. Pharm. Res. 12:1865-1868 (1995).
43. K. Midha, M. Rawson, and J. Hubbard. Bioequivalence: switchability and scaling. Eur. J. Pharm. Sci. 6:87-91 (1998).
44. L. Tothfalusi, and L. Endrenyi. Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm. Res. 20:382-389 (2003).
45. max. Int. J. Clin. Pharmacol. Ther. 41:217-225 (2003).
46. V. Karalis, P. Macheras, and M. Symillides. Geometric mean ratio dependent scaled bioequivalence limits with levelling-off properties. Eur. J. Pharm. Sci. 26:54-61 (2005).
47. V. Karalis, M. Symillides, and P. Macheras. Novel scaled average bioequivalence limits based on GMR and variability considerations. Pharm. Res. 21:1933-1942 (2004).
48. J. Kytariolos, V. Karalis, P. Macheras, and M. Symillides. Novel scaled bioequivalence limits with levelling-off properties. Pharm. Res. 23:2657-2664 (2006).
49. S. Haidar, B. Davit, M.-L. Chen, D. Conner, L. Lee, Q. Li, R. Lionberger, F. Makhlouf, D. Patel, D. Schuirmann, and L. Yu. Bioequivalence approaches for highly variable drugs and drug products. Pharm. Res. 25(1):237-241 (2008).